Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00324727 · ClinicalTrials.gov registry record · Phase 3
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
A Phase 3 study, sponsored by Delcath Systems.
- Completed
- Registry status
- Phase 3
- Development phase
- 93
- Enrollment target
NCT00324727 is a Phase 3 study that has completed, run by Delcath Systems. The registered enrollment target is 93 participants.
The verdict
NCT00324727, a Phase 3 study, has completed, sponsored by Delcath Systems.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 93 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving melphalan directly into the arteries around the tumor may kill more tumor cells. It is not yet known whether hepatic arterial infusion with melphalan is more effective than standard therapy in treating liver metastases due to melanoma. PURPOSE: This randomized phase III trial is studying hepatic arterial infusion with melphalan to see how well it works compared to standard therapy in treating patients with unresectable liver metastases due to melanoma.
Interventions
- DRUG melphalan
- DRUG systemic chemotherapy
- DRUG regional chemotherapy
- PROCEDURE hepatic artery embolization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2006-02 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00324727
The ClinicalTrials.gov registry entry for NCT00324727 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Delcath Systems, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which melphalan is the first listed.
NCT00324727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00324727 about?
NCT00324727 is a clinical study titled "Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma". RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving melphalan directly into the arteries around the tumor may kill more tumor cells. It is not yet known whether hepat...
What is the current status of trial NCT00324727?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 93 participants. The study started on 2006-02. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00324727?
The interventions under investigation include: melphalan (DRUG), systemic chemotherapy (DRUG), regional chemotherapy (DRUG), hepatic artery embolization (PROCEDURE).
Who is sponsoring clinical trial NCT00324727?
This trial is sponsored by Delcath Systems, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.